Xbrane Biopharma AB (OSTO:XBRANE) Margin of Safety % (DCF FCF Based): N/A (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:XBRANE Xbrane Biopharma AB OSTO:XBRANE
71 GF Score
Price kr9.18
GF Value kr6.00
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Xbrane Biopharma AB Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Xbrane Biopharma AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

OSTO:XBRANE vs VRTX, REGN, RVMD: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Xbrane Biopharma AB's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xbrane Biopharma AB Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Margin of Safety % (DCF FCF Based) falls into.


OSTO:XBRANE
71GF Score
Xbrane Biopharma AB OSTO:XBRANE
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xbrane Biopharma AB (OSTO:XBRANE) Overvalued in 2026?

Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued. The current stock price of kr9.18 is trading 53% above its estimated GF Value™ of kr6.00. GuruFocus considers Xbrane Biopharma AB to be Significantly Overvalued.

Key valuation signals for OSTO:XBRANE:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: kr6.00 vs. price of kr9.18 (53% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the OSTO:XBRANE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xbrane Biopharma AB Business Description

Other Exchanges 7XB0:Germany
Address Scheeles vag 5, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
71GF Score

Get the complete analysis for OSTO:XBRANE

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr9.18
Price
kr6.00
GF Value